The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer (Q41566518)

3 October 2017

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer (English)

1 reference

3 October 2017

14

Howard I Scher

1 reference

3 October 2017

Himisha Beltran

1

1 reference

3 October 2017

Adam Jendrisak

2

1 reference

3 October 2017

Mark Landers

3

1 reference

3 October 2017

Juan Miguel Mosquera

4

1 reference

3 October 2017

Myriam Kossai

5

1 reference

3 October 2017

Jessica Louw

6

1 reference

3 October 2017

Rachel Krupa

7

1 reference

3 October 2017

Ryon P Graf

8

1 reference

3 October 2017

Nicole A Schreiber

9

1 reference

3 October 2017

David M Nanus

10

1 reference

3 October 2017

Scott T Tagawa

11

1 reference

3 October 2017

Dena Marrinucci

12

1 reference

3 October 2017

Ryan Dittamore

13

1 reference

3 October 2017

language of work or name

English

0 references

publication date

15 December 2015

1 reference

3 October 2017

Clinical Cancer Research

1 reference

3 October 2017

22

1 reference

3 October 2017

6

1 reference

3 October 2017

1510-1519

1 reference

Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases

3 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

6 June 2018

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Circulating tumor cells: a multifunctional biomarker

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

European cancer mortality predictions for the year 2014.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Aggressive variants of castration-resistant prostate cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Proposed morphologic classification of prostate cancer with neuroendocrine differentiation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

The epigenetics of epithelial-mesenchymal plasticity in cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Physical biology in cancer. 2. The physical biology of circulating tumor cells

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Platinum-based chemotherapy for variant castrate-resistant prostate cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

High speed detection of circulating tumor cells.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Case study of the morphologic variation of circulating tumor cells.

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Erratum: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer

2 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4990782

Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26671992

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26671992

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-15-0137

1 reference

3 October 2017

1 reference

3 October 2017

PubMed publication ID

26671992

1 reference